HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: M300094-JLR200v1 44/10/1887    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chandler, C. E. Articles by Harwood, H. J. Search for Related Content PubMed PubMed Citation Articles by Chandler, C. E. Articles by Harwood, H. J., Jr. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 44, 1887-1901, October 2003
Copyright © 2003 by American Society for Biochemistry and Molecular Biology

CP-346086

Charles E. Chandler, Donald E. Wilder, Judith L. Pettini, Yvette E. Savoy, Stephen F. Petras, George Chang, John Vincent and H. James Harwood, Jr.¹

Department of Cardiovascular and Metabolic Diseases, Pfizer Global Research and Development, Groton Laboratories, Pfizer, Inc., Eastern Point Road, Groton, CT 06340

¹ To whom correspondence should be addressed. e-mail: h_james_harwood{at}groton.pfizer.com

A microsomal triglyceride transfer protein (MTP) inhibitor, CP-346086, was identified that inhibited both human and rodent MTP activity [concentration giving half-maximal inhibition (IC₅₀) 2.0 nM]. In Hep-G2 cells, CP-346086 inhibited apolipoprotein B (apoB) and triglyceride secretion (IC₅₀ 2.6 nM) without affecting apoA-I secretion or lipid synthesis. When administered orally to rats or mice, CP-346086 lowered plasma triglycerides [dose giving 30% triglyceride lowering (ED₃₀) 1.3 mg/kg] 2 h after a single dose. Coadministration with Tyloxapol demonstrated that triglyceride lowering was due to inhibition of hepatic and intestinal triglyceride secretion. A 2 week treatment with CP-346086 lowered total, VLDL, and LDL cholesterol and triglycerides dose dependently with 23%, 33%, 75%, and 62% reductions at 10 mg/kg/day. In these animals, MTP inhibition resulted in increased liver and intestinal triglycerides when CP-346086 was administered with food. When dosed away from meals, however, only hepatic triglycerides were increased. When administered as a single oral dose to healthy human volunteers, CP-346086 reduced plasma triglycerides and VLDL cholesterol dose dependently with ED₅₀s of 10 mg and 3 mg, and maximal inhibition (100 mg) of 66% and 87% when measured 4 h after treatment. After a 2 week treatment (30 mg/day), CP-346086 reduced total and LDL cholesterol and triglycerides by 47%, 72%, and 75%, relative to either individual baselines or placebo, with little change in HDL cholesterol.

Together, these data support further evaluation of CP-346086 in hyperlipidemia.

Abbreviations: CETP, cholesterol ester transfer protein; CHD, coronary heart disease; ER, endoplasmic reticulum; MTP, microsomal triglyceride transfer protein

Supplementary key words microsomal triglyceride transfer protein • lipid transfer inhibition • very low density lipoprotein • low density lipoprotein • apolipoprotein B • apolipoprotein A-I • Hep-G2 cells

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. Iqbal, L. L. Rudel, and M. M. Hussain Microsomal Triglyceride Transfer Protein Enhances Cellular Cholesteryl Esterification by Relieving Product Inhibition J. Biol. Chem., July 18, 2008; 283(29): 19967 - 19980. [Abstract] [Full Text] [PDF]

				M. F. Essop, H. S. Camp, C. S. Choi, S. Sharma, R. M. Fryer, G. A. Reinhart, P. H. Guthrie, A. Bentebibel, Z. Gu, G. I. Shulman, et al. Reduced heart size and increased myocardial fuel substrate oxidation in ACC2 mutant mice Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H256 - H265. [Abstract] [Full Text] [PDF]

				X. Pan, F. N. Hussain, J. Iqbal, M. H. Feuerman, and M. M. Hussain Inhibiting Proteasomal Degradation of Microsomal Triglyceride Transfer Protein Prevents CCl4-induced Steatosis J. Biol. Chem., June 8, 2007; 282(23): 17078 - 17089. [Abstract] [Full Text] [PDF]

				R. A. Hegele, M. Cuchel, and D. J. Rader Familial Hypercholesterolemia N. Engl. J. Med., April 26, 2007; 356(17): 1779 - 1780. [Full Text] [PDF]

				H. Huang, F. Sun, D. M. Owen, W. Li, Y. Chen, M. Gale Jr., and J. Ye From the Cover: Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins PNAS, April 3, 2007; 104(14): 5848 - 5853. [Abstract] [Full Text] [PDF]

				M. Lamant, F. Smih, R. Harmancey, P. Philip-Couderc, A. Pathak, J. Roncalli, M. Galinier, X. Collet, P. Massabuau, J.-M. Senard, et al. ApoO, a Novel Apolipoprotein, Is an Original Glycoprotein Up-regulated by Diabetes in Human Heart J. Biol. Chem., November 24, 2006; 281(47): 36289 - 36302. [Abstract] [Full Text] [PDF]

				N. J. Spann, S. Kang, A. C. Li, A. Z. Chen, E. P. Newberry, N. O. Davidson, S. T. Y. Hui, and R. A. Davis Coordinate Transcriptional Repression of Liver Fatty Acid-binding Protein and Microsomal Triglyceride Transfer Protein Blocks Hepatic Very Low Density Lipoprotein Secretion without Hepatosteatosis J. Biol. Chem., November 3, 2006; 281(44): 33066 - 33077. [Abstract] [Full Text] [PDF]

				J. J.P. Kastelein, M. K. Wedel, B. F. Baker, J. Su, J. D. Bradley, R. Z. Yu, E. Chuang, M. J. Graham, and R. M. Crooke Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B Circulation, October 17, 2006; 114(16): 1729 - 1735. [Abstract] [Full Text] [PDF]

				J. Mao, F. J. DeMayo, H. Li, L. Abu-Elheiga, Z. Gu, T. E. Shaikenov, P. Kordari, S. S. Chirala, W. C. Heird, and S. J. Wakil Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis PNAS, May 30, 2006; 103(22): 8552 - 8557. [Abstract] [Full Text] [PDF]

				C. D. Rochester and C. E. Cooke The Changing Face of Dyslipidemia Therapies Journal of Pharmacy Practice, April 1, 2006; 19(2): 79 - 93. [Abstract] [PDF]

				R. M. Crooke, M. J. Graham, K. M. Lemonidis, C. P. Whipple, S. Koo, and R. J. Perera An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis J. Lipid Res., May 1, 2005; 46(5): 872 - 884. [Abstract] [Full Text] [PDF]

				R. M. Cantor, T. de Bruin, N. Kono, S. Napier, A. van Nas, H. Allayee, and A. J. Lusis Quantitative Trait Loci for Apolipoprotein B, Cholesterol, and Triglycerides in Familial Combined Hyperlipidemia Pedigrees Arterioscler. Thromb. Vasc. Biol., October 1, 2004; 24(10): 1935 - 1941. [Abstract] [Full Text] [PDF]